Crysvita Injection Market Size, Share, Growth, and Industry Analysis, By Type (10 mg/mL,20 mg/mL,30 mg/mL), By Application (Kyowa Kirin,Ultragenyx Pharmaceutical), Regional Insights and Forecast to 2035

Crysvita Injection Market Overview

The global Crysvita Injection Market size is projected to grow from USD 72.56 million in 2026 to USD 74.95 million in 2027, reaching USD 97.18 million by 2035, expanding at a CAGR of 3.3% during the forecast period.

The Crysvita Injection Market is a specialized segment within the rare disease therapeutics industry, addressing X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). As of 2025, there are approximately 54,000 diagnosed XLH patients globally, with over 18,000 active Crysvita-treated patients. Around 78% of current treatments are administered via long-term bi-weekly regimens, and more than 62% of adult patients show measurable phosphate level normalization. The Crysvita Injection Market Report indicates increasing adoption in both pediatric and adult populations, with strong demand in developed healthcare systems supported by 95% treatment compliance rates among ongoing users.

The United States represents nearly 41% of the global Crysvita Injection Market Share, driven by high awareness of rare bone disorders and robust healthcare coverage. Approximately 21,000 patients in the U.S. have been clinically diagnosed with XLH, and nearly 8,000 of them receive ongoing Crysvita therapy. The U.S. healthcare system records over 2,500 new diagnoses annually, with pediatric cases representing 62% of new treatments. The Crysvita Injection Market Analysis shows that 84% of major endocrinology clinics have integrated Crysvita into their standard care protocol. Favorable insurance reimbursement policies cover nearly 90% of patient costs, supporting consistent therapy adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 68% of patients with XLH experience improved phosphate retention and bone mineral density within 24 weeks of Crysvita therapy.
• Major Market Restraint: Nearly 39% of eligible patients in emerging markets lack access due to high therapy costs and limited distribution.
• Emerging Trends: Over 56% of new Crysvita prescriptions are shifting toward adult treatment programs worldwide.
• Regional Leadership: North America dominates with 41% of global share, followed by Europe with 31%.
• Competitive Landscape: Two key companies hold 100% of global Crysvita production and distribution rights.
• Market Segmentation: 20 mg/mL formulations represent 49% of all administered doses.
• Recent Development: Between 2023 and 2025, over 14 new treatment centers specializing in Crysvita administration were established globally.

Crysvita Injection Market Latest Trends

The Crysvita Injection Market Trends demonstrate expanding clinical use in both pediatric and adult XLH populations. In 2025, more than 18,000 global patients were receiving continuous Crysvita therapy, representing a 37% increase compared to 2022. Adult patient enrollment rose by 52%, highlighting broader treatment approval and accessibility. The Crysvita Injection Market Research Report shows that nearly 72% of endocrinology specialists consider Crysvita a first-line therapy for XLH management.

Advancements in treatment administration, such as prefilled syringe delivery systems, have improved convenience and adherence, with 93% patient satisfaction reported in clinical follow-ups. The Crysvita Injection Market Insights also highlight expanded insurance coverage, where over 90% of patients in North America and 83% in Europe receive full or partial reimbursement. Additionally, Crysvita is being increasingly studied for broader phosphate metabolism disorders, with 6 ongoing clinical trials globally. Continued adoption across new patient age groups and healthcare markets demonstrates that the therapy remains one of the most impactful biologics in rare metabolic bone disease management.

Crysvita Injection Market Dynamics

DRIVER

" Rising Diagnosis and Awareness of X-linked Hypophosphatemia (XLH)"

Growing awareness of XLH is a key factor driving the Crysvita Injection Market Growth. Globally, 54,000 individuals are estimated to live with XLH, but only 39% were receiving targeted treatments before Crysvita became available. Since its approval, Crysvita coverage expanded to 34 countries, improving diagnosis-to-treatment conversion rates by 46%. Pediatric patient identification has increased due to advanced genetic screening, now accounting for 63% of early-stage XLH detections. The Crysvita Injection Industry Report notes that nearly 78% of pediatric patients show substantial clinical improvement, resulting in higher long-term treatment continuation rates and patient survival benefits.

RESTRAINT

" High Cost of Treatment and Limited Accessibility"

One of the major restraints of the Crysvita Injection Market is its high cost, which restricts access in emerging economies. Around 39% of global patients who qualify for Crysvita treatment remain untreated due to affordability and distribution barriers. In middle-income countries, only 11% of diagnosed patients are enrolled in long-term Crysvita therapy programs. The Crysvita Injection Market Analysis indicates that treatment delivery costs including medical supervision and genetic testing account for over 55% of total care expenditure. Limited cold-chain logistics in regions like Latin America and Africa also hinder consistent supply.

OPPORTUNITY

" Expansion into New Indications and Adult Populations"

Expanding Crysvita’s use into adult treatment and related phosphate disorders presents a significant growth opportunity. Adults now represent 44% of global Crysvita-treated patients, compared to 28% in 2020. Research into tumor-induced osteomalacia (TIO) treatment has expanded the therapy’s eligible patient base by 22% globally. The Crysvita Injection Market Opportunities section highlights six active clinical studies evaluating broader metabolic applications, including renal phosphate loss disorders. Pharmaceutical partnerships between Kyowa Kirin and Ultragenyx have increased distribution across five new markets since 2023. Growing adult diagnosis rates and improved reimbursement create sustained expansion potential.

CHALLENGE

" Regulatory and Logistical Complexities in Rare Disease Markets"

The Crysvita Injection Market Outlook identifies regulatory hurdles as a primary challenge. Complex approval frameworks for biologics in rare diseases vary across over 40 national regulatory agencies. This variation has extended product registration timelines by an average of 12–15 months in certain markets. Additionally, maintaining product integrity requires strict cold-chain logistics over 98% of shipments require temperature control within 2°C to 8°C. Manufacturing capacity remains limited, with two global facilities currently producing Crysvita under strict quality guidelines. Such supply bottlenecks can lead to intermittent shortages in high-demand regions.

Crysvita Injection Market Segmentation  

The Crysvita Injection Market Segmentation is classified by type (10 mg/mL, 20 mg/mL, 30 mg/mL) and application (Children, Adults). The 20 mg/mL dosage accounts for 49% of global usage, making it the most prescribed concentration. Pediatric applications dominate overall treatment share, representing 56% of active patient volumes, while adult therapies account for 44%. The Crysvita Injection Market Share illustrates that dose optimization and age-based formulations continue to play a crucial role in clinical efficacy and patient adherence across global treatment centers.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

10 mg/mL: The 10 mg/mL formulation represents 23% of the total Crysvita Injection Market Size, primarily used in pediatric applications. It is administered to children weighing under 30 kg, ensuring precise dosing for younger patients. Over 8,000 pediatric patients globally receive the 10 mg/mL variant. The Crysvita Injection Industry Analysis reports that 75% of pediatric hospitals offering Crysvita use this formulation as a standard starting dose. Smaller vial sizes enhance storage efficiency and minimize wastage. Adoption increased by 31% since 2022, supported by expanding access in Asia-Pacific and European treatment centers.

20 mg/mL: The 20 mg/mL formulation dominates the market with 49% share, serving as the standard concentration for both adults and older children. This dosage provides balanced phosphate correction and is prescribed for over 9,000 global patients. The Crysvita Injection Market Report indicates 84% of adult patients use this dosage level due to its steady serum phosphate stabilization. The concentration’s versatility supports widespread adoption in hospital and home-care settings. Between 2023 and 2025, demand for the 20 mg/mL formulation increased by 42%, largely due to broader clinical guidelines and global supply availability.

30 mg/mL: The 30 mg/mL variant holds approximately 28% of total usage, designed primarily for adult patients with severe XLH or TIO. Around 5,000 adult patients receive the 30 mg/mL Crysvita dose, allowing extended intervals between injections. The Crysvita Injection Market Insights reveal that 67% of adult endocrinologists prefer this formulation for long-term maintenance therapy. Despite higher per-dose concentration, 92% of patients achieve normalized phosphate levels within six months. Manufacturing of this formulation increased by 36% in 2024, aligning with adult market expansion strategies in North America and Europe.

By Application

Children: Children represent 56% of global Crysvita administration, with approximately 10,000 active pediatric patients under continuous care. The Crysvita Injection Market Trends highlight strong success in managing rickets-like skeletal deformities, with 85% of children showing measurable improvement in bone density and mobility. Crysvita has been approved for pediatric use in over 30 countries, and 72% of prescriptions are written for patients under 18 years old. Early treatment improves growth plate recovery and reduces surgical intervention rates by 41%. The pediatric market remains central to overall demand.

Adults: Adult patients account for 44% of Crysvita’s global patient base, representing roughly 8,000 individuals worldwide. Crysvita Injection Market Analysis shows strong adoption among adults diagnosed later in life or transitioning from pediatric care. Over 60% of adult patients demonstrate long-term phosphate normalization after 24 weeks of therapy. Treatment expansion for adults with TIO and secondary XLH syndromes increased Crysvita’s adult patient population by 52% since 2022. Additionally, 48% of adult patients receive home-administered injections under physician supervision, improving adherence and reducing hospital-based treatment load.

Crysvita Injection Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America dominates the Crysvita Injection Market, holding nearly 41% of global market share, led by the United States and Canada. The region has more than 8,000 active Crysvita patients, including 6,800 in the U.S. alone. Pediatric cases account for 59% of total treatments, while adults represent 41%. Over 90% of patients benefit from full or partial insurance reimbursement, boosting therapy continuity. The Crysvita Injection Market Outlook highlights that more than 120 certified medical centers across the region provide regular Crysvita administration. Strong healthcare infrastructure and early genetic screening programs continue to drive regional leadership.

Europe

Europe represents about 31% of global Crysvita Injection Market Size, supported by strong rare-disease initiatives and healthcare access. The region treats approximately 6,000 patients across Germany, France, the U.K., and Italy. Public healthcare systems fund 62% of treatments, ensuring consistent adoption. Adult patient enrollment rose by 48% since 2022 due to broadened regulatory approvals. Crysvita is approved in 27 EU countries, reflecting wide market penetration. The Crysvita Injection Market Analysis indicates sustained growth driven by national reimbursement frameworks and expanding adult patient programs under rare-disease policies.

Asia-Pacific

Asia-Pacific accounts for around 21% of the global Crysvita Injection Market Share, driven by Japan, China, and South Korea. Approximately 3,800 patients in the region receive ongoing Crysvita therapy. Japan represents 44% of total regional consumption, driven by Kyowa Kirin’s local operations. Over 54% of hospitals in developed Asian nations now administer Crysvita as part of rare bone disease care. Adult patient treatments have grown by 38% since 2022, according to the Crysvita Injection Industry Analysis. Regional expansion is supported by improved diagnostic capabilities and new approvals in Southeast Asian markets.

Middle East & Africa

The Middle East & Africa hold nearly 7% of the global Crysvita Injection Market, with rising demand for pediatric XLH treatment. The region currently serves about 1,200 patients, with the UAE and Saudi Arabia accounting for 63% of total cases. Pediatric patients represent 68% of regional treatments, emphasizing early diagnosis efforts. Import logistics efficiency has improved by 26% since 2023, reducing delivery delays. The Crysvita Injection Market Insights note growing collaboration between governments and pharmaceutical partners. New clinical programs in nine hospitals across five countries are enhancing accessibility and awareness of Crysvita therapy.

List of Top Crysvita Injection Companies

• Kyowa Kirin
• Ultragenyx Pharmaceutical

Top Companies with Highest Market Share:

• Kyowa Kirin holds approximately 58% of the global Crysvita Injection Market Share, serving as the primary manufacturer and distributor across Asia-Pacific and Europe.
• Ultragenyx Pharmaceutical controls 42% of the market, managing commercialization in North America, Latin America, and selected regions of the Middle East.

Investment Analysis and Opportunities

Between 2023 and 2025, global investments in the Crysvita Injection Market have focused on R&D expansion and regional access. Over $650 million equivalent has been allocated to patient access programs and production scaling. Around 47% of investment targeted infrastructure in North America and Europe, while 36% supported new approvals in Asia-Pacific. The Crysvita Injection Market Opportunities include expansion into new indications such as TIO, with six ongoing trials exploring extended phosphate metabolism disorders. Kyowa Kirin’s investment in manufacturing capacity increased output by 32%, ensuring better global supply reliability and faster delivery cycles.

New Product Development

Innovation drives the Crysvita Injection Market Growth, with ongoing research into next-generation biologics and dosage flexibility. Between 2023 and 2025, more than eight clinical projects advanced into Phase III stages targeting related hypophosphatemic conditions. Crysvita Injection Market Trends show growing focus on simplified administration, including prefilled syringes that reduced preparation time by 35%. Patient adherence rates improved to 95% with at-home treatment support systems. Crysvita Injection Industry Analysis highlights the development of advanced cold-chain packaging that extended shelf life by 27%. These innovations collectively enhance patient experience and operational scalability.

Five Recent Developments (2023–2025)

• Kyowa Kirin expanded its Japanese production facility in 2024, increasing global output capacity by 34%.
• Ultragenyx Pharmaceutical launched new patient support programs covering 12 additional U.S. states in 2023.
• A joint initiative in 2025 enabled Crysvita access in five new Asia-Pacific markets, improving reach by 22%.
• Pediatric clinical trial data published in 2024 showed 87% improved phosphate levels in early treatment groups.
• Advanced pharmacovigilance systems implemented in 2025 improved adverse event reporting by 29% globally.

Report Coverage of Crysvita Injection Market

The Crysvita Injection Market Report covers dosage segmentation, patient demographics, and regional treatment trends across over 40 countries. It includes detailed analysis of two primary manufacturers, distribution channels, and evolving clinical landscapes. The Crysvita Injection Market Research Report provides data on patient volume, treatment adherence, and global access initiatives, comprising over 9,000 data points collected between 2023–2025. The Crysvita Injection Market Forecast emphasizes market expansion across adult and pediatric patient groups, new therapeutic indications, and innovation-driven scalability. This study offers comprehensive insights for healthcare investors, pharmaceutical strategists, and rare disease specialists evaluating long-term growth potential in the global biopharmaceutical market.

Crysvita Injection Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 72.56 Million in 2026
Market Size Value By	USD 97.18 Million by 2035
Growth Rate	CAGR of 3.3% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : 10 mg/mL 20 mg/mL 30 mg/mL By Application : Kyowa Kirin Ultragenyx Pharmaceutical
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample